A high-margin, recurring “razor-and-blade” plasma leader in valuation purgatory—awaiting hospital/interventional re-acceleration and a post-CSL growth reveal.
Overview
Haemonetics is a specialized med-tech company built around blood and plasma management with an increasingly diversified footprint. Its model combines capital equipment placement with high-margin, recurring consumable and software revenue, creating strong predictability and attractive margins. The company operates across three segments—Plasma, Hospital, and Blood Center—while executing a multi-year transformation from a plasma-centric identity into a higher-growth hospital-focused med-tech (interventional cardiology and advanced diagnostics). Plasma remains a foundational profit engine (~43% of FY24 revenue), led by NexSys PCS with Persona technology that increases plasma yield and center productivity, supported by integrated donor management software (NexLynk DMS). Hospital is the primary growth engine (~41.5% of FY25 revenue), driven by TEG hemostasis analyzers (BMT franchise) and VASCADE vascular closure devices (Interventional franchise). Blood Center has been rationalized toward higher-margin apheresis and away from lower-margin whole blood. The U.S. is the core market (~74% of revenue), reflecting the concentration of global source plasma collection in the U.S. Customers choose Haemonetics for measurable clinical and economic outcomes—higher yield in plasma and clinically proven safety/efficiency advantages in vascular closure—supported by service infrastructure, workflow integration, and switching costs. The investment debate centers on whether the company can translate these structural strengths into sustained growth and a valuation rerating as major transitions (notably the CSL customer shift) roll off and hospital momentum stabilizes.